Stephen J. Freedland, MD

Related Content

Services

• Prostate Cancer
• Urology

Department / Division:
Surgery / Urology

Address:
DUMC 2626
Durham, NC 27710

Appointment Telephone:
919-668-5946

Office Telephone:
919-668-8361

Fax Telephone:
919-668-7093

• MD, University of California, Davis, School of Medicine 1997

• General Surgery, UCLA School of Medicine (California)
• Urology, UCLA School of Medicine (California), 2003

• Urologic Oncology Fellowship, Johns Hopkins University School of Medicine (Maryland), 2003-2005

Clinical Interests:
Prostate cancer and prostate diseases

Research Interests:
Prostate cancer
Obesity
Nutrition
Diet
Outcomes and database analyses
Statistical modeling
risk stratification
PSA
Biomarkers

Representative Publications:
Nielsen ME, Han M, Mangold L, Humphreys E, Walsh PC, Partin AW, Freedland SJ. Black race does not independently predict adverse outcome following radical retropubic prostatectomy at a tertiary referral center. J Urol. 2006 Aug;176(2):515-9. (2006) Abstract

Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ. Pathological Outcomes and Biochemical Progression in Men With T1c Prostate Cancer Undergoing Radical Prostatectomy With Prostate Specific Antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. J Urol. 2006 Aug;176(2):554-8. (2006) Abstract

Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, Terris MK. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006 Feb;175(2):500-4; discussion 504. (2006) Abstract

Freedland SJ, Partin AW. Prostate-specific antigen: update 2006. Urology. 2006 Mar;67(3):458-60. (2006) Abstract

Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Presti JC Jr, Terris MK, . Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol. 2006 Apr;175(4):1298-302; discussion 1302-3. (2006) Abstract

Freedland SJ, Giovannucci E, Platz EA. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control. 2006 Feb;17(1):5-9. (2006) Abstract

Haffner MC, Landis PK, Saigal CS, Carter HB, Freedland SJ. Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: impact of neurovascular bundle preservation. Urology. 2005 Aug;66(2):371-6. (2005) Abstract

Freedland SJ. Obesity and prostate cancer: a growing problem. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6763-6. (2005) Abstract

Freedland SJ, Terris MK, Platz EA, Presti JC Jr. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology. 2005 Jul;66(1):108-13. (2005) Abstract

Freedland SJ, Mangold LA, Walsh PC, Partin AW. The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy. J Urol. 2005 Oct;174(4 Pt 1):1276-81; discussion 1281; author reply 1281. (2005) Abstract

Freedland SJ, Isaacs WB. Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate. 2005 Feb 15;62(3):243-52. (2005) Abstract

Freedland SJ, Isaacs WB, Platz EA, Terris MK, Aronson WJ, Amling CL, Presti JC Jr, Kane CJ. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol. 2005 Oct 20;23(30):7546-54. (2005) Abstract

Freedland SJ, Isaacs WB, Mangold LA, Yiu SK, Grubb KA, Partin AW, Epstein JI, Walsh PC, Platz EA. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res. 2005 Apr 15;11(8):2883-8. (2005) Abstract

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005 Jul 27;294(4):433-9. (2005) Abstract

Freedland SJ, Haffner MC, Landis PK, Saigal CS, Carter HB. Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy. Urology. 2005 Jun;65(6):1131-6. (2005) Abstract

Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, Epstein JI, Partin AW. Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol. 2005 Nov;174(5):1798-801; discussion 1801. (2005) Abstract

Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, Isaacs WB, Partin AW. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol. 2005 Sep;174(3):919-22. (2005) Abstract

Freedland SJ, Aronson WJ. Obesity and prostate cancer. Urology. 2005 Mar;65(3):433-9. (2005) Abstract

Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, DeKERNION JB, Freedland SJ. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004 Jun;171(6 Pt 1):2260-4. (2004) Abstract

Ngo TH, Barnard RJ, Anton T, Tran C, Elashoff D, Heber D, Freedland SJ, Aronson WJ. Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. Cancer Res. 2004 Feb 15;64(4):1252-4. (2004) Abstract

Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B, Aronson WJ, . Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol. 2004 Aug;172(2):520-4. (2004) Abstract

Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Aronson WJ, . Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol. 2004 Jun;171(6 Pt 1):2215-20. (2004) Abstract

Freedland SJ, Presti JC Jr, Kane CJ, Aronson WJ, Terris MK, Dorey F, Amling CL, . Do younger men have better biochemical outcomes after radical prostatectomy? Urology. 2004 Mar;63(3):518-22. (2004) Abstract

Freedland SJ, Partin AW, Epstein JI, Walsh PC. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer. 2004 Apr 15;100(8):1646-9. (2004) Abstract

Freedland SJ, Mangold LA, Epstein JI, Partin AW. Biopsy indication--a predictor of pathologic stage among men with preoperative serum PSA levels of 4.0 ng/mL or less and T1c disease. Urology. 2004 May;63(5):887-91. (2004) Abstract

Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Presti JC Jr, Trock B, Amling CL. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. Cancer. 2004 Aug 15;101(4):748-53. (2004) Abstract

Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, Terris MK. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004 Feb 1;22(3):446-53. (2004) Abstract

Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology. 2003 Feb;61(2):365-9. (2003) Abstract

Freedland SJ, Presti JC Jr, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL, . Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. J Urol. 2003 Jun;169(6):2129-35. (2003) Abstract

Freedland SJ, Presti JC Jr, Amling CL, Kane CJ, Aronson WJ, Dorey F, Terris MK, . Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003 Apr;61(4):736-41. (2003) Abstract

Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC Jr, . Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol. 2003 Jun;169(6):2136-41. (2003) Abstract

Freedland SJ, Aronson W, Presti JC Jr, Kane CJ, Terris MK, Elashoff D, Amling CL, . Should a positive surgical margin following radical prostatectomy be pathological stage T2 or T3? Results from the SEARCH database. J Urol. 2003 Jun;169(6):2142-6. (2003) Abstract

Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J Urol. 2002 Feb;167(2 Pt 1):516-20. (2002) Abstract

Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC Jr, Terris MK, Aronson WJ, . Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology. 2002 Oct;60(4):670-4. (2002) Abstract

Freedland SJ, Sutter ME, Naitoh J, Dorey F, Csathy GS, Aronson WJ. Clinical characteristics in black and white men with prostate cancer in an equal access medical center. Urology. 2000 Mar;55(3):387-90. (2000) Abstract

Freedland SJ, Jalkut M, Dorey F, Sutter ME, Aronson WJ. Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center. Urology. 2000 Jul;56(1):87-91. (2000) Abstract